Mortality Increased With Exposure to Coal Fine Particulate Matter
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 27, 2023 -- Exposure to fine particulate matter (PM2.5) resulting from coal electricity-generating unit (EGU) sulfur dioxide emissions (coal PM2.5) is associated with 2.1 times greater mortality than exposure to PM2.5 from other sources, according to a study published online Nov. 23 in Science.
Lucas Henneman, Ph.D., from George Mason University Volgenau School of Engineering in Fairfax, Virginia, and colleagues estimated the number of deaths attributable to coal PM2.5 from 480 coal EGUs from 1999 to 2020 using individual-level Medicare death records representing 650 million person-years.
The researchers found that a 1 μg/m3 increase in annual average coal PM2.5 was associated with a 1.12 percent increase in all-cause mortality; the mortality risk was 2.1 times higher with exposure to coal PM2.5 versus exposure to PM2.5 from all other sources. Overall, 460,000 deaths were attributable to coal PM2.5, representing 25 and 7 percent of all PM2.5-related Medicare deaths before 2009 and after 2012, respectively.
"PM2.5 from coal has been treated as if it's just another air pollutant. But it's much more harmful than we thought, and its mortality burden has been seriously underestimated," Henneman said in a statement. "These findings can help policymakers and regulators identify cost-effective solutions for cleaning up the country's air; for example, by requiring emissions controls or encouraging utilities to use other energy sources, like renewables."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-28 00:32
Read more
- The Right Time is Now to Get Your Flu Vaccine
- Standing More During the Day Does Not Cut Cardiovascular Risk
- Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds
- Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
- COVID-19 Burden in Hospitals Affects Risk for In-Hospital Adverse Events
- USPSTF Recommends Screening for Domestic Violence in Pregnant, Postpartum Women
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions